Cargando…

Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium

Drug resistance to chemotherapy is often associated with increased malignancy in neuroblastoma (NB). In pursuit of alternative treatments for chemoresistant tumour cells, we tested the response of multidrug-resistant SKNSH and of vincristine (VCR)-, doxorubicin (DOX)-, or cisplatin (CDDP)-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blaheta, R A, Michaelis, M, Natsheh, I, Hasenberg, C, Weich, E, Relja, B, Jonas, D, Doerr, H W, Cinatl, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359931/ https://www.ncbi.nlm.nih.gov/pubmed/17505515 http://dx.doi.org/10.1038/sj.bjc.6603777

Ejemplares similares

Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression
por: Blaheta, Roman A, et al.
Publicado: (2006)

Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine
por: Dudley, A C, et al.
Publicado: (2008)

MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome
por: Ryan, J, et al.
Publicado: (2012)

Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-γ
por: Ribatti, D, et al.
Publicado: (2006)

Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer
por: Nitzsche, B, et al.
Publicado: (2012)

Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours
por: Mendoza, J, et al.
Publicado: (2013)

Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells
por: Fung, M K L, et al.
Publicado: (2006)

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
por: Atmaca, A, et al.
Publicado: (2007)

Hexokinase 2 is a determinant of neuroblastoma metastasis
por: Edry Botzer, Liat, et al.
Publicado: (2016)

In vivo effects of rosiglitazone in a human neuroblastoma xenograft
por: Cellai, I, et al.
Publicado: (2010)

Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
por: Uchino, H, et al.
Publicado: (2005)

Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells
por: Cellai, I, et al.
Publicado: (2006)

Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells
por: Armstrong, J L, et al.
Publicado: (2005)

Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01
por: Yeow, W-S, et al.
Publicado: (2006)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
por: Barker, S E, et al.
Publicado: (2007)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
por: Pasquier, E, et al.
Publicado: (2013)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

ATP7A is a novel target of retinoic acid receptor β(2) in neuroblastoma cells
por: Bohlken, A, et al.
Publicado: (2009)

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
por: Chen, L, et al.
Publicado: (2014)

Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt
por: Yang, X, et al.
Publicado: (2008)

Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo
por: Armstrong, J L, et al.
Publicado: (2007)

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
por: Cai, W, et al.
Publicado: (2010)

Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model
por: Chiu, B, et al.
Publicado: (2014)

Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts
por: Chaudary, Naz, et al.
Publicado: (2017)

Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response
por: Ivarsson, K, et al.
Publicado: (2005)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
por: Dean, E J, et al.
Publicado: (2010)

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
por: Meng, F, et al.
Publicado: (2013)

Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines
por: Lindner, D, et al.
Publicado: (2009)

Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations
por: Bodo, J, et al.
Publicado: (2006)

Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
por: Graat, H C A, et al.
Publicado: (2006)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform
por: Almeida, Gilberto S, et al.
Publicado: (2017)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model
por: Girard, E, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_b30icpdtmkbkj4ff6rodkov70p